Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its effi cacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.
Introduction
Lung cancer remains the leading cause of cancer death globally, and outcomes for patients diagnosed with advanced non-small-cell lung cancer are poor despite recent advances in treatment. 1 Docetaxel has been the standard of care for second-line or third-line treatment; however, its effi cacy is off set by substantial toxic eff ects.
The new development of antibodies that target the programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) pathway represents an important advance in the management of metastatic non-small-cell lung cancer, with PD-1 inhibitors showing overall survival benefi ts over docetaxel. Compared with docetaxel, nivolumab has shown a median overall survival of 9·2 months versus 6·0 months (hazard ratio [HR] 0·59, 95% CI 0·44-0·79) in squamous non-small-cell lung cancer and 12·2 months versus 9·4 months (96% CI 0·73, 0·59-0·89) in non-squamous non-small-cell lung cancer. 2, 3 Additionally, pembrolizumab compared with docetaxel has shown a median overall survival of 10·4 months versus 8·5 months (HR 0·71, 95% CI 0·58-0·88) at the approved dose of 2 mg/kg in a patient population with non-small-cell lung cancer who expressed PD-L1 in 1% or more of tumour cells. 4 PD-L1 is an immune checkpoint protein expressed on tumour cells and tumour-infi ltrating immune cells. PD-L1 can mediate suppression of anticancer immunity by binding to its receptors PD-1 and B7-1 (also known as CD80). [5] [6] [7] Atezolizumab is a humanised engineered IgG1 monoclonal antibody targeting PD-L1 and thus has a mechanism of action distinct from anti-PD-1 antibodies. In addition to blocking the PD-L1 and PD-1 interaction, which can reinvigorate suppressed immune cells to eliminate cancer cells, [8] [9] [10] atezolizumab blocks PD-L1 and B7-1 binding, which might further enhance immune responses. [11] [12] [13] [14] Furthermore, direct targeting of PD-L1 leaves the PD-L2 and PD-1 interaction intact and might minimise autoimmunity. 8, 15, 16 A phase 1 study 17 of atezolizumab monotherapy has shown durable antitumour responses in non-small-cell lung cancer and has shown an association of PD-L1 expression on tumour cells and tumour-infi ltrating immune cells with patients who had an objective response. 9 In the phase 2, randomised POPLAR study, 18, 19 atezolizumab improved overall survival compared with docetaxel in patients with previously treated non-smallcell lung cancer (12·6 months vs 9·7 months; HR 0·69, 95% CI 0·52-0·92) in the intention-to-treat (ITT) population. Additionally, results from POPLAR suggested that there are two distinct subpopulations of non-small-cell lung cancer that can be identifi ed through PD-L1 expression on tumour cells and tumour-infi ltrating immune cells, with PD-L1 expression on tumour cells or tumour-infi ltrating immune cells independently contributing to overall survival. 18 We report the primary analysis of the OAK study, the fi rst, to our knowledge, phase 3 study of a PD-L1-directed antibody (atezolizumab). OAK was designed to investigate the effi cacy and safety of atezolizumab compared with docetaxel in patients with locally advanced or metastatic, previously treated non-small-cell lung cancer.
Research in context
Evidence before this study Docetaxel has been the standard of care for second-line or third-line treated, advanced, or metastatic non-small-cell lung cancer. Important advancements in the treatment of non-smallcell lung cancer have come from cancer immunotherapies that target the programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) pathway. We searched PubMed from Sept 27, 2011, to Sept 27, 2016, for clinical trials with the terms "non-small cell lung cancer", "programmed death-ligand 1", "PD-L1", "programmed death-1", "PD-1", and "cancer immunotherapy", selecting relevant English language publications within the past 5 years. We identifi ed eight studies (phases 1-3, all of which were international and open-label) of atezolizumab, pembrolizumab, or nivolumab. These studies indicated the therapeutic value of targeting of the PD-L1 and PD-1 pathway to treat non-small-cell lung cancer, and that atezolizumab shows durable responses and an overall survival benefi t for this disease. These responses were associated with PD-L1 expression on tumour cells and tumour-infi ltrating immune cells.
Added value of this study
To our knowledge, OAK is the fi rst phase 3 randomised clinical trial to report results for an anti-PD-L1 antibody. In our study, atezolizumab showed a signifi cant and clinically relevant improvement in overall survival compared with docetaxel in patients with advanced stage, previously treated non-small-cell lung cancer, regardless of histology or PD-L1 expression, with a favourable safety profi le compared with docetaxel. Patients with tumours expressing high levels of PD-L1 (≥50% on tumour cells or ≥10% on tumour-infi ltrating immune cells) derived the greatest benefi t from atezolizumab. In contrast to data from PD-1 antibodies, overall survival was also improved in patients with little or no PD-L1 expression (<1% on tumour cells and tumour-infi ltrating immune cells). There was a survival benefi t of atezoliumab over docetaxel across clinical subgroups, including in patients with squamous and non-squamous disease, in the present and previous smokers population, and in the never smokers population, which has been associated with lower mutational heterogeneity and immunogenicity.
Implications of all the available evidence
Together with reports of the anti-PD1 antibodies pembrolizumab and nivolumab, our results affi rm that not only the PD-1 receptor but also the ligand components (eg, PD-L1) of the pathway are valid targets for the treatment of lung cancer. Targeting of PD-L1 with atezolizumab results in a clinically relevant improvement of overall survival as well as a favourable safety profi le compared with docetaxel in patients with previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology. Atezolizumab is the fi rst checkpoint inhibitor to provide an overall survival benefi t in patient populations who are historically less responsive to these agents, including patients with low or non-detectable levels of PD-L1 expression and never smokers.
See Online for appendix
Methods

Study design
OAK is a randomised, open-label, international phase 3 study that was done in 194 academic medical centres and community oncology practices across 31 countries worldwide. The study was done in full accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki.
Patients
Patients had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had received 1-2 previous cytotoxic chemotherapy regimens (≥1 platinum based combination therapy) for stage IIIB or IV non-small-cell lung cancer. Patients with EGFR mutations or an ALK fusion oncogene were additionally required to have received previous tyrosine kinase inhibitor therapy. Patients with treated asymptomatic supratentorial CNS metastases were eligible, whereas patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded (appendix). All patients gave written informed consent.
Randomisation and masking
Patients were stratifi ed by PD-L1 expression (IC0 vs IC1 vs IC2 vs IC3 level), number of previous chemotherapy regimens (one vs two), and histology (non-squamous vs squamous). PD-L1 expression was assessed centrally and prospectively in archival or fresh tumour samples according to previously published scoring criteria 18 with the VENTANA SP142 PD-L1 immunohistochemistry assay (Ventana Medical Systems, Inc., Tucson, AZ, USA). TC1/2/3 or IC1/2/3 was defi ned as PD-L1 expression on 1% or more of tumour cells or tumour-infi ltrating immune cells, TC2/3 or IC2/3 was defi ned as PD-L1 expression on 5% of these cells; TC3 was defi ned as PD-L1 expression on 50% or more of tumour cells and IC3 was defi ned as 10% or more of tumour-infi ltrating immune cells; and TC0 as PD-L1 expression on less than 1% of tumour cells and IC0 on less than 1% of tumour-infi ltrating immune cells (appendix). PD-L1 gene expression was assessed in tumour tissue with a Fluidigm-based gene-expression platform as previously described (Fluidigm; South San Francisco, CA, USA). 18 Permuted block-randomisation (block size of eight) via an interactive voice or web response system (bracket) was used to assign patients in a 1:1 ratio to receive atezolizumab or docetaxel. The trial centres enrolled the patients. The study was open-label and allocation was unmasked.
Procedures
Atezolizumab was given as an intravenous 1200 mg fi xed dose every 3 weeks; docetaxel was given intravenously at 75 mg/m² every 3 weeks. Treatment was administered until unacceptable toxicity or disease progression, as assessed by the investigator. Atezolizumab treatment could continue beyond disease progression if the investigator deemed the patient to be receiving clinical benefi t. No crossover to atezolizumab was allowed.
Tumour assessments were done at baseline, then every 6 weeks until week 36 and every 9 weeks thereafter. These assessments continued until disease progression, regardless of treatment discontinuation. For patients receiving atezolizumab beyond disease progression, tumour assessments continued until treatment discontinuation. Patients were followed up for survival throughout the study while receiving treatment and every 3 months after treatment discontinuation.
Outcomes
The primary endpoint was overall survival compared between treatment groups within the ITT and the PD-L1 TC1/2/3 or IC1/2/3 populations (PD-L1 expression on ≥1% of tumour cells or tumour-infi ltrating immune cells 18 ). Secondary endpoints included investigator-assessed progression-free survival, proportion of patients who had an objective response, duration of response, and safety.
Safety was assessed descriptively and based on all patients who received any dose of study treatment. The incidence, nature, and severity of adverse events and laboratory abnormalities were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
20
Statistical analysis
OAK was initially designed to enrol 850 patients, and the sample size was later increased to enrol up to 1300 patients to power for an overall survival comparison in patients with high PD-L1 expression (TC3 or IC3, assuming a prevalence of approximately 20%); the fi nal enrolment was 1225 patients. Data from the phase 2 randomised study POPLAR 18 showed that the overall survival benefi t extended to lower PD-L1 expression levels and that the assessment of this benefi t required a relatively long follow-up because of the late separation of survival curves. Therefore, the OAK statistical design was amended on Jan 28, 2016, according to a prespecifi ed modifi cation plan to test overall survival in the ITT population and in the TC1/2/3 or IC1/2/3 population in a coprimary fashion (with α splitting between the ITT population [α=3%] and the TC1/2/3 or IC1/2/3 population [α=2%]) for which the initial 850 randomised patients provided suffi cient power (95·3% in the ITT population and 98·6% in the TC1/2/3 or IC1/2/3 population) and follow-up time. Therefore, the primary effi cacy analysis population comprises the fi rst 850 patients who were randomly assigned to a treatment group.
The primary analysis of overall survival was planned when approximately 70% of patients in the primary effi cacy analysis population had died. Overall survival was compared between treatment groups with a stratifi ed logrank test at the two-sided signifi cance level. The KaplanMeier approach was used to estimate the median overall survival; the Brookmeyer-Crowley methodology was used to estimate 95% CIs. The HR was estimated with a stratifi ed Cox regression analysis. Stratifi cation factors were the same used for randomisation. Prespecifi ed analyses were done to determine the consistency of the treatment eff ect according to key baseline characteristics and in diff erent subgroups of patients according to their tumour PD-L1 expression level. Given the exploratory nature of subgroup analyses and potential small sample sizes in specifi c subgroups, the HRs from these analyses were estimated with an unstratifi ed Cox regression analysis. Patients not reported as having died at the time of analysis were censored at the date they were last known to be alive. Patients without post-baseline information were censored at the randomisation date plus 1 day.
Progression-free survival and duration of response were analysed with the same methods as the overall survival analysis. The proportion of patients with an objective response and the corresponding 95% CIs for each treatment group were calculated with the Clopper-Pearson method and compared between treatment groups with the Cochran-Mantel-Haenszel test.
An independent data monitoring committee reviewed safety. Protocol approval was obtained from independent ethics committees for each site (listed in the appendix). Statistical analyses were done with the SAS version 9.2. This study is registered with ClinicalTrials.gov, number NCT02008227.
Role of the funding source
The funder of the study provided study drugs, was involved in the study design, data collection, data analysis, data interpretation, and writing of the report, and gave approval to submit for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between March 11, 2014, and Nov 28, 2014, 850 patients in the primary analysis population were recruited at 194 academic or community oncology centres across 31 countries; 425 patients were randomised to receive atezolizumab and 425 to receive docetaxel (ITT population; fi gure 1). Demographic and baseline characteristics were well balanced between groups (table 1; appendix). Enrolment of the fi nal 375 patients took place until April 29, 2015. Of the fi nal 1225 patients randomly assigned in the total patient population, 609 patients received atezolizumab and 578 patients received docetaxel (safety population). 125 (21%) of 609 patients in the atezolizumab group and 14 (2%) of 578 patients in the docetaxel group had a treatment duration longer than 12 months. Median treatment duration was 3·4 months (range 0-26) with atezolizumab and 2·1 months (range 0-23) with docetaxel. 40% of patients receiving atezolizumab were treated beyond progression, with a median treatment duration beyond progression of three cycles (range 1-34).
At the primary analysis (data cutoff July 7, 2016), the median follow-up was 21 months and 569 patients had died (271 in the atezolizumab group and 298 in the docetaxel group; event to patient ratio 67%). Compared with docetaxel, overall survival was better with atezolizumab in both the ITT and TC1/2/3 or IC1/2/3 populations (fi gures 2A, 2B Progression-free survival was similar between treatment groups in the ITT population (HR 0·95 [95% CI 0·82-1·10]). Median progression-free survival was 2·8 months (95% CI 2·6-3·0) with atezolizumab and 4·0 months (3·3-4·2) with docetaxel (table 2, appendix). The proportion of patients with an objective response in the ITT population was also similar between treatment groups (table 2) . However, median duration of response in the ITT population was notably longer in the atezolizumab group at 16·3 months (95% CI 10·0-not evaluable) compared with 6·2 months (4·9-7·6) in the docetaxel group (table 2) . At the time of data cutoff , responses were ongoing in 30 (52%) of 58 patients in the atezolizumab group and in ten (18%) of 57 patients in the docetaxel group.
Overall survival was improved regardless of PD-L1 expression levels (fi gure 2C-F): patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) derived benefi t from atezolizumab treatment over docetaxel (median overall survival 12·6 months [95% CI 9·6-15·2] vs 8·9 months [7·7-11·5]; HR 0·75 [95% CI 0·59-0·96]; fi gure 2E). These results are consistent with our analysis of PD-L1 gene expression in tumour tissue, which showed an overall survival benefi t in patients with lower than median expression of PD-L1 (50% prevalence; HR 0·74 [95% CI 0·58-0·96]; appendix). Patients with high PD-L1 expression (TC3 or IC3 subgroup) derived the greatest benefi t from atezolizumab (median overall survival 20·5 months [95% CI 17·5-not evaluable] vs 8·9 months [5·6-11·6]; HR 0·41 [95% CI 0·27-0·64]; fi gure 2D). Although overall survival improvement was noted in all PD-L1 expression subgroups, including the PD-L1 low or undetectable subgroup, the interaction test analysis of mutually exclusive PD-L1 groups and treatment indicated that PD-L1 expression might be a modifi er of treatment eff ect on overall survival (appendix); however, this fi nding might be attributed to the pronounced overall survival benefi t at the highest expression level (TC3 or IC3; fi gure 2). To assess the independent contribution of PD-L1 expression on tumour cells or tumour-infi ltrating immune cells we analysed non-overlapping subgroups. In the TC1/2/3 and IC0 subgroup, median overall survival was 13·2 months (95% CI 7·8-20·5) with atezolizumab and 12·0 months (3·7-14·7) with docetaxel (HR 0·72 [95% CI 0·36-1·45]). In the TC0 and IC1/2/3 subgroup, median overall survival was 14·3 months (95% CI 10·6-18·4) with atezolizumab and 9·8 months (7·3-13·7) with docetaxel (HR 0·73, 95% CI 0·52-1·02). Point estimates for the overall survival HR in both subgroups Progression-free survival was similar in both treatment arms in PD-L1 subgroups (including the TC1/2/3 or IC1/2/3 population; table 2, appendix), with the exception of the TC3 or IC3 group, which showed a greater benefi t with atezolizumab than with docetaxel Figure 4B shows all adverse events with a diff erence in incidence between groups of 5% or more. Of those, pruritus was more common with atezolizumab than with docetaxel. Musculoskeletal pain was more common with atezolizumab but rates of myalgia were higher with docetaxel. Adverse events occurring in 10% or more of patients in any group are shown in the appendix.
In the 609 patients in the safety analysis, immunemediated adverse events reported with atezolizumab included pneumonitis (six [1%] patients at any grade; four [<1%] patients at grade 3, hepatitis (two [<1%] patients, both grade 3), and colitis (two [<1%] patients, both grade 2).
Adverse events leading to treatment discontinuation occurred in 46 (8%) of 609 patients with atezolizumab and in 108 (19%) of 578 patients with docetaxel. There were no deaths related to atezolizumab and one related to docetaxel (respiratory tract infection).
Discussion
To our knowledge, OAK, the fi rst randomised phase 3 trial of a PD-L1-targeted therapy, met its coprimary endpoint, showing that atezolizumab treatment resulted in a signifi cant improvement in overall survival compared with docetaxel in patients with advanced stage non-small-cell lung cancer (in the ITT and TC1/2/3 or IC1/2/3 populations) whose disease had progressed during or after platinum-based chemotherapy. These clinically meaningful data confi rm the results of a phase 2 study (POPLAR), 18 and both studies show improved survival irrespective of PD-L1 expression status and histology (squamous and nonsquamous), as well as increased durable responses with atezolizumab in non-small-cell lung cancer.
Of note, 17% of patients treated with docetaxel received subsequent cancer immunotherapies, predominantly the PD-1-targeted therapy nivolumab. Given the survival benefi t provided by these agents in patients with previously treated non-small-cell lung cancer, this might have resulted in increased survival in the docetaxel group and a diminution in measured overall survival diff erence between groups.
Consistent with the POPLAR study, patients with tumours expressing high levels of PD-L1 (TC3 or IC3) derived the greatest benefi t from atezolizumab. In this study, overall survival was also improved in patients with less than 1% PD-L1 expression (ie, TC0 and IC0 subgroup). These immunohistochemistry data are supported by a similar overall survival benefi t noted in patients with low PD-L1 levels by gene expression analysis. By contrast, the proportion of TC0 and IC0 patients with an objective response is lower than that in those patients with higher PD-L1 expression, which is consistent with what was reported for anti-PD-1 inhibitors and in previous atezolizumab studies. Because low PD-L1 expression is associated with weak or no preexisting anticancer immunity, 18 this observed survival benefi t associated with atezolizumab in patients who are PD-L1-negative warrants additional investigation to HR was stratifi ed for progression-free survival in the ITT and TC1/2/3 or IC1/2/3 populations; unstratifi ed for other subgroups and duration of response. *n=58 for the atezolizumab group and n=57 for the docetaxel group. †n=43 for the atezolizumab group and n=36 for the docetaxel group. HR=hazard ratio. IC=tumour infi ltrating immune cells.
ITT=intention-to-treat. NE=not evaluable. TC=tumour cell. (26) 156 (18) 694 (82) 85 (10) 765 (90) 59 (7) 203 (24) 85 (10) 628 (74) 850 (100) better understand the mechanisms of response to therapy in this patient population. These include the biological hypothesis that atezolizumab increases anticancer immunity through enhanced priming of new anticancer immune responses.
The overall survival HRs favoured atezolizumab over docetaxel across other clinical subgroups, including the never smokers population. Although the confi dence intervals for HR in this subgroup were too wide to show a conclusive benefi t, this fi nding supports further evaluation given the low mutational heterogeneity and immunogenicity as well as minimal activity noted with PD-1 inhibitors in this population. In contrast to observations in PD-1 inhibitor studies, 2,3 patients with treated CNS metastases at baseline seemed to derive benefi t from atezolizumab treatment. Conversely, patients with EGFR mutation-positive disease received similar overall survival benefi t with atezolizumab and docetaxel. This fi nding is similar to results reported with anti-PD-1 treatment in this clinical setting 3 and might suggest decreased immunogenicity in this subgroup of patients. Subgroup analyses were not powered for formal effi cacy comparisons and should be interpreted with caution.
As seen in other trials with PD-L1 and PD-1 antibodies, [2] [3] [4] 18 progression-free survival and the proportion of patients with an objective response in the ITT population were not improved with atezolizumab compared with docetaxel in OAK. The apparent discordance between progression-free survival and overall survival might be due to an initial increase in tumour volume from increased immune infi ltration, delayed antitumour activity, or antitumour immune activation beyond progression that might be sustained by continued treatment. 21 This discordance has been commonly observed in studies of this drug class. As such, at least for patients with lower PD-L1 expression levels, these data confi rm that progression-free survival results underestimate the clinical benefi t measured by overall survival for atezolizumab. The concept of postprogression prolongation of survival has been previously introduced for EGFR inhibitor therapies 22 and the OAK results imply that this eff ect can occur with atezolizumab treatment. These observations also support further evaluation of the benefi t and risk of continuing atezolizumab treatment until loss of clinical benefi t. 22 Overall, atezolizumab was well tolerated, with a favourable adverse event profi le compared with docetaxel, and observed adverse events were consistent with those previously reported with atezolizumab. 18 The proportion of patients who experienced grade 3 or 4 adverse events, treatment-related adverse events, and those leading to discontinuation of study treatment was lower with atezolizumab than with docetaxel. The incidence of specifi c immune-related adverse events was low, including pneumonitis (with 1% overall occurrence and less than 1% being grade 3, with no grade 4 events), which is of particular relevance to patients with lung cancer.
In conclusion, this phase 3 study of a PD-L1-directed antibody, atezolizumab, shows a clinically meaningful 
Atezolizumab (n=609) Docetaxel (n=578)
All adverse events 573 (94%) 555 (96%) survival benefi t over docetaxel in previously treated patients with non-small-cell lung cancer regardless of PD-L1 expression or histology, with a favourable safety profi le compared with docetaxel. These clinically relevant data support atezolizumab as a new treatment option for patients with advanced non-small-cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
